Member Info for desamax

Pg 54

Not too sure if up to date but took this from the below report that I belt is dated this year, forgive me if I have got this wrong.
“ Another oral CHK1 inhibitor,SRA737, when combined with low dose gemcitabine,enhances the effect of anti-PD-L1 in a small cell lungcancer model by significantly increasing antitumorigenicCD8+cytotoxic T-cell, dendritic cell, and M1 macrophagepopulations through activation of STING and interferonsignaling and induction of expression of PD-L1 andinflammatory chemokines.114Moreover, in an unbiasedlarge-scale siRNA screen, SRA737 is found to be syntheti-cally lethal in combination with subunits of the B-familyof DNA polymerases, POLA1, POLE, and POLE2 inhuman non-small cell lung cancer and colorectal cancercell line”

https://onlinelibrary.wiley.com/doi/pdf/10.1002/aac2.12047

It is also now apparent that the HNWI never came onboard for the covid stance. It’s more and more likely they knew and now know what’s on the horizon.
GLA

New at ten story on Cine coming up

Gropelad why don’t you go back further than 12 mths and let us know how much we have gained??
We know maths is not your strong subject, not long now before your back behind your school desk, roll on sept.

I know of a couple of LTHs who sold on the drop during the Q&A last week, maybe one of them has come back in. Let’s see if anyone puts their hand up.

Gorper what a melt !

It’s been a very quite year for news from the BoD so far when you compare it to others, and yet a lot is happening. Our resident snoops have been working overtime to dig out snippets of info. Something must be about to erupt to warrant the £5m + investment that is yet to come to fruition.
Best of luck to everyone

From Sept 2018…..
Dr Tim Mitchell, CEO of Sareum, commented: “TYK2 and JAK1 have emerged in recent years as important targets for new drugs with potential to treat a broad range of autoimmune diseases. This has naturally led to some serious interest from the major pharmaceutical companies, including Pfizer, Bristol-Myers Squibb and Celgene having their own clinical and preclinical programmes in this area. With SDC-1801, we believe we are entering this space with a strong candidate that exhibits potentially best-in-class features. We intend to focus our resources on advancing SDC-1801 through preclinical development and into clinical trials over the next 18 months. At the same time, we will continue our discussions with potential licence partners for this exciting drug candidate.”

Sareum has an ongoing co-development agreement with SRI International (Menlo Park, CA, USA) to develop TYK2 inhibitors in autoimmune diseases. Sareum retains commercialisation rights for these and other TYK2 inhibitors with profiles optimised for oncology indications.

Another Great spot potnak, here the journal report mentioned in the RNS…
https://www.jimmunol.org/content/193/7/3278

With all the great research and digging over the past few days and possibly more finds to come. Could we get an announcement before the Q & A. I’m hopeful and have everything crossed

Took a punt here in 2008, made a few hundred quid. Then started to do some research and read most of T2s post, I would’ve been happy with his 7p prediction that subsequently got exceeded. I’m happy to sit on my 30 K shares and see what happens on this journey all thanks to the one and T2
Here’s hoping you make a speedy recovery if anyone deserves the fruits of SAR, it’s you sir.

Tomorrow
https://www.investis-live.com/gsk/62c7fa19d9438014006f2453/opopp

Fantastic work fellow LTHs I wonder when the bod will make the announcement to the market, surly if what’s been researched and backed by the documents found they can’t keep silent for much longer GLA

https://www.globenewswire.com/news-release/2022/05/25/2450257/0/en/Dexamethasone-Market-to-Reach-1-052-Million-Globally-by-2031-at-6-0-CAGR-Growth-Plus-Reports.html

https://www.google.com/amp/s/www.theweek.in/news/health/2022/06/20/covid-19--the-inside-story-of-recovery.amp.html

Sustained-release, intraoperatively administered

anti-inflammatory drugs, such as DEXYCU (dexamethasone intraocular suspension 9%), are emerging as alternatives to topical drops as a strategy for minimizing inflammation following ocular surgery. In this article, the authors summarize available literature on intraocular dexamethasone and describe the evolution of their administration technique.
https://www.dovepress.com/real-world-experience-with-intracapsular-administration-of-dexamethaso-peer-reviewed-fulltext-article-OPTH

Thanks HBD
Worth watching biotech stocks in US. Lots of money on side line and this sector has been hit badly. Sar/serria will benefit from this imo

https://www.bloomberg.com/news/articles/2022-06-03/bristol-myers-to-pay-4-1-billion-for-lung-cancer-biotech?srnd=deals

Why are we not showcasing here ?
https://beta.asco.org/?s_tnt=161267:0:0&adobe_mc_sdid=SDID%3D587C0C43AEFBB895-463C9C192A69CB82%7CMCORGID%3DFC92401053DA88170A490D4C@AdobeOrg%7CTS%3D1654214400

Above my paywall but plenty of links to tyk2

Resi boffins can connect MMP-9 and MMP12, if appropriate.

https://www.pharmatimes.com/news/birmingham_research_shows_promise_for_spinal_cord_injury_patients_1448677

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872272/

Kat how do you know the HNWI are not linked to eachother?